• Je něco špatně v tomto záznamu ?

The risk factors for oral mucositis and the effect of cryotherapy in patients after the BEAM and HD-l-PAM 200 mg/m(2) autologous hematopoietic stem cell transplantation

S. Vokurka, E. Bystricka, J. Scudlova, E. Mazur, M. Visokaiova, E. Vasilieva, R. Brandejsova, I. Chvojkova, M. Vrabcova, J. Vitkova, D. Mjartanova, M. Vodickova, J. Bockova, K. Streinerova

. 2011 ; 15 (5) : 508-512. [pub] 20110210

Jazyk angličtina Země Velká Británie

Typ dokumentu klinické zkoušky, časopisecké články, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc12022269

PURPOSE: Oral mucositis (OM) still represents a significant complication of hematopoietic stem cell transplantations (HSCT). Observational studies focusing on risk factor definitions are still warranted. METHOD: A total of 126 patients participated in this observational study after autologous HSCT with the BEAM and HD-l-PAM 200mg/m(2) conditioning regimens. Basic clinical and laboratory variables and their impact on OM were assessed. RESULTS: Age, gender, body mass index, and baseline absolute neutrophil counts were not shown to have any negative impact on OM development. The multivariate analysis revealed oral cryotherapy non-provision as being the most significant predictor for OM incidence (p < 0.0001), followed by BEAM conditioning regimen (p = 0.007), OM in a patient's history (p = 0.002) and lower number of days since the last chemotherapy (p = 0.025). The cryotherapy was remarkably effective both in the single high-dose melphalan 200mg/m(2) conditioning regimen (18% OM in cryotherapy vs. 68% without it, p<0.0001) and in the multidrug BEAM (melphalan 140mg/m(2)) regimen (38% vs. 86%, p=0.006). CONCLUSION: Oral cryotherapy should be implemented into supportive care management in patients treated with high-dose melphalan short-infusion chemotherapy. Large and well-designed randomized trials are necessary to obtain more significant and reliable results and understanding regarding OM risk factors.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc12022269
003      
CZ-PrNML
005      
20201109140519.0
007      
ta
008      
120806s2011 xxk f 000 0#eng||
009      
AR
024    7_
$a 10.1016/j.ejon.2011.01.006 $2 doi
035    __
$a (PubMed)21310656
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Vokurka, Samuel $7 mzk2005309233 $u University Hospital Pilsen, Haematology-Oncology, Plzen, Czech Republic
245    14
$a The risk factors for oral mucositis and the effect of cryotherapy in patients after the BEAM and HD-l-PAM 200 mg/m(2) autologous hematopoietic stem cell transplantation / $c S. Vokurka, E. Bystricka, J. Scudlova, E. Mazur, M. Visokaiova, E. Vasilieva, R. Brandejsova, I. Chvojkova, M. Vrabcova, J. Vitkova, D. Mjartanova, M. Vodickova, J. Bockova, K. Streinerova
520    9_
$a PURPOSE: Oral mucositis (OM) still represents a significant complication of hematopoietic stem cell transplantations (HSCT). Observational studies focusing on risk factor definitions are still warranted. METHOD: A total of 126 patients participated in this observational study after autologous HSCT with the BEAM and HD-l-PAM 200mg/m(2) conditioning regimens. Basic clinical and laboratory variables and their impact on OM were assessed. RESULTS: Age, gender, body mass index, and baseline absolute neutrophil counts were not shown to have any negative impact on OM development. The multivariate analysis revealed oral cryotherapy non-provision as being the most significant predictor for OM incidence (p < 0.0001), followed by BEAM conditioning regimen (p = 0.007), OM in a patient's history (p = 0.002) and lower number of days since the last chemotherapy (p = 0.025). The cryotherapy was remarkably effective both in the single high-dose melphalan 200mg/m(2) conditioning regimen (18% OM in cryotherapy vs. 68% without it, p<0.0001) and in the multidrug BEAM (melphalan 140mg/m(2)) regimen (38% vs. 86%, p=0.006). CONCLUSION: Oral cryotherapy should be implemented into supportive care management in patients treated with high-dose melphalan short-infusion chemotherapy. Large and well-designed randomized trials are necessary to obtain more significant and reliable results and understanding regarding OM risk factors.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a protokoly protinádorové kombinované chemoterapie $x aplikace a dávkování $x škodlivé účinky $x terapeutické užití $7 D000971
650    _2
$a karmustin $x aplikace a dávkování $x škodlivé účinky $7 D002330
650    _2
$a kryoterapie $7 D017679
650    _2
$a cytarabin $x aplikace a dávkování $x škodlivé účinky $7 D003561
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a rozvrh dávkování léků $7 D004334
650    _2
$a etoposid $x aplikace a dávkování $x škodlivé účinky $7 D005047
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a transplantace hematopoetických kmenových buněk $x škodlivé účinky $7 D018380
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a melfalan $x aplikace a dávkování $x škodlivé účinky $7 D008558
650    _2
$a lidé středního věku $7 D008875
650    _2
$a prospektivní studie $7 D011446
650    _2
$a rizikové faktory $7 D012307
650    _2
$a stomatitida $x etiologie $x prevence a kontrola $7 D013280
650    _2
$a příprava pacienta k transplantaci $x škodlivé účinky $x metody $7 D019172
650    _2
$a autologní transplantace $7 D014182
650    _2
$a výsledek terapie $7 D016896
650    _2
$a mladý dospělý $7 D055815
655    _2
$a klinické zkoušky $7 D016430
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Bystřická, Eva $7 xx0118051 $u University Hospital Pilsen, Haematology-Oncology, Alej Svobody 80, Plzen, Czech Republic
700    1_
$a Ščudlová, Jana $7 xx0127129 $u University Hospital Olomouc, Haemato-Oncology, I.P.Pavlova 6, Olomouc, Czech Republic
700    1_
$a Mazur, Ewa $u Silesian Medical Academy Katowice, Silesian Medical Academy, Dep. of Haematology and BMT, Katowice, Poland
700    1_
$a Visokaiova, Maria $u Pasteur University Hospital Kosice, University Hospital, Haematology and Haemato-Oncology, Trieda SNP 1, Kosice, Slovakia
700    1_
$a Vasilieva, Elizabeth $u Pavlov Medical University St.Petersburg, Centre of Haematology, St. Petersburg, Russia
700    1_
$a Brandejsová, Renáta $7 xx0122020 $u University Hospital Pilsen, Haematology-Oncology, Alej Svobody 80, Plzen, Czech Republic
700    1_
$a Chvojková, Ivana $7 _AN076888 $u University Hospital Pilsen, Haematology-Oncology, Alej Svobody 80, Plzen, Czech Republic
700    1_
$a Vrabcová, Martina $u University Hospital Pilsen, Haematology-Oncology, Alej Svobody 80, Plzen, Czech Republic
700    1_
$a Vítková, Jitka $7 xx0126227 $u University Hospital Olomouc, Haemato-Oncology, I.P.Pavlova 6, Olomouc, Czech Republic
700    1_
$a Mjartanová, Dagmar $7 xx0128782 $u University Hospital Olomouc, Haemato-Oncology, I.P.Pavlova 6, Olomouc, Czech Republic
700    1_
$a Vodičková, Marcela. $7 xx0262629 $u University Hospital Olomouc, Haemato-Oncology, I.P.Pavlova 6, Olomouc, Czech Republic
700    1_
$a Bocková, Jana $7 xx0197872 $u Pasteur University Hospital Kosice, University Hospital, Haematology and Haemato-Oncology, Trieda SNP 1, Kosice, Slovakia
700    1_
$a Streinerová, Katerina $u University Hospital Pilsen, Haematology-Oncology, Alej Svobody 80, Plzen, Czech Republic
773    0_
$w MED00153922 $t European journal of oncology nursing the official journal of European Oncology Nursing Society $x 1532-2122 $g Roč. 15, č. 5 (2011), s. 508-512
856    41
$u https://pubmed.ncbi.nlm.nih.gov/21310656 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y m $z 0
990    __
$a 20120806 $b ABA008
991    __
$a 20201109140516 $b ABA008
999    __
$a ok $b bmc $g 944182 $s 779566
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2011 $b 15 $c 5 $d 508-512 $e 20110210 $i 1532-2122 $m European journal of oncology nursing $n Eur. j. oncol. nurs. $x MED00153922
LZP    __
$b NLK111 $a Pubmed-20120806/12/01

Najít záznam

Citační ukazatele

Možnosti archivace